RESUMO
Several P4 domain derivatives of the general d-phenylglycinamide-based scaffold (2) were synthesized and evaluated for their ability to bind to the serine protease factor Xa. Some of the more potent compounds were evaluated for their anticoagulant effects in vitro. A select subset containing various P1 indole constructs was further evaluated for their pharmacokinetic properties after oral administration to rats.
Assuntos
Antitrombina III/síntese química , Antitrombina III/farmacologia , Glicina/análogos & derivados , Anticoagulantes/síntese química , Anticoagulantes/química , Anticoagulantes/farmacologia , Antitrombina III/química , Cristalografia por Raios X , Fator Xa/química , Fator Xa/metabolismo , Glicina/síntese química , Glicina/química , Glicina/farmacologia , Humanos , Modelos Moleculares , Estrutura Molecular , Ligação Proteica , Relação Estrutura-AtividadeRESUMO
Several non-amidino S1 derivatives of the 1,2-diaminobenzene-based scaffold (4) were synthesized and evaluated for their ability to bind to the active site and inhibit the human protease factor Xa. A subset of these compounds were also evaluated for their anticoagulant effects in human plasma as measured by prothrombin time (PT).
Assuntos
Anticoagulantes/síntese química , Derivados de Benzeno/síntese química , Inibidores do Fator Xa , Anticoagulantes/farmacologia , Derivados de Benzeno/farmacologia , Sítios de Ligação , Coagulação Sanguínea/efeitos dos fármacos , Fator Xa/metabolismo , Humanos , Modelos Moleculares , Inibidores de Proteases/síntese química , Inibidores de Proteases/farmacologia , Ligação Proteica , Tempo de Protrombina , Relação Estrutura-AtividadeRESUMO
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) is a basic carboxypeptidase that functions as a fibrinolysis inhibitor through the cleavage of C-terminal lysine on partially degraded fibrin. Modulation of TAFI activity provides a potential therapy for thrombosis complications by potentiating fibrinolysis. In our study, we identified three novel TAFI inhibitors containing a cysteine backbone. Three cysteine derivatives, guanidinyl-L-cysteine, glycyl-L-cysteine, and glycyl-glycyl-L-cysteine were tested in TAFI substrate assays and showed K(app)(i)=0.08, 0.14, and 0.99 microM, respectively. Subsequent fibrinolysis assays confirmed their TAFI inhibitory activities. Guanidinyl-L-cysteine showed inhibitory activity in a human plasma clot lysis assay (IC(50)=9.4 microM). Identification of these cysteine derivatives represents an opportunity to develop potent and specific TAFI inhibitors.